Filtreler
Universal markers of thyroid malignancies: Galectin-3, HBME-1, and Cytokeratin-19

Barut F. | Kandemir N.O. | Bektas S. | Bahadir B. | Keser S. | Ozdamar S.O.

Article | 2010 | Endocrine Pathology21 ( 2 ) , pp.80 - 89

Difficulties in diagnosis of thyroid lesions, even with histologic analysis, are well known. This study has been carried on to evaluate the role of immunohistochemical markers including galectin-3, Hector Battifora mesothelial cell-1 (HBME-1), and cytokeratin-19 in the diagnosis and differential diagnosis of benign and malignant thyroid lesions. The expressions of galectin-3, HBME-1, and cytokeratin-19 were tested in formalin-fixed, paraffin-embedded tissues from 458 surgically resected thyroid lesions including non-neoplastic and neoplastic lesions. Immunostaining with standard avidin-biotin complex technique was performed by using . . . monoclonal antibodies. In malignant neoplastic thyroid lesions, galectin-3, HBME-1, and cytokeratin-19 were diffusely expressed in general. Diffuse expression rates of these three markers were 72.3% (47/65), 70.7% (46/65), and 76.9% (50/65), respectively. The use of galectin-3, HBME-1, and cytokeratin-19 may provide significant contributions in the differential diagnosis of malignant thyroid tumors. Although focal galectin-3, HBME-1, and cytokeratin-19 expression may be encountered in benign lesions, diffuse positive reactions for these three markers are characteristic of malignant lesions. It has concluded that cytokeratin-19 alone and its combinations with other markers were more sensitive in accurate diagnosis of papillary carcinoma than the other combinations; meanwhile, there were similar results for follicular carcinomas with HBME-1 alone and its combinations. © 2009 Springer Science+Business Media, LLC Daha fazlası Daha az

The value of cytokeratin-19 immunohistochemistry in the differential diagnosis of papillary thyroid carcinomas

Barut F. | Bektaş S. | Bahadir B. | Onak Kandemir N. | Karadayi N. | Özdamar Ş.O.

Article | 2009 | Turkiye Klinikleri Journal of Medical Sciences29 ( 1 ) , pp.42 - 47

Objective: The gold standard for diagnosis of papillary thyroid carcinoma is conventional histology, which depends on the characteristic nuclear features, regardless of whether papillary architecture is present or not. This study was carried on to evaluate the utility of cytokeratin-19 in the diagnosis and differential diagnosis of papillary thyroid carcinoma. Material and Methods: Expression of cytokeratin-19 was tested on formalin-fixed, paraffin-embedded tissues from 380 surgically resected thyroid lesions including hyperplasic nodules (n= 243), granulomatous thyroiditis (n= 3), lymphocytic (n= 53) and Hashimoto's thyroiditis (n= . . . 11), follicular adenomas (n= 17), Hurthle cell adenomas (n= 4), well-differentiated thyroid tumor with follicular architecture of uncertain malignant potenti al (n= 1), papillary carcinomas (n= 45), follicular carcinoma (n= 1), insular carcinoma (n= 1), and medullary carcinoma (n= 1). The immunoreactivity was scored as negative, 1+, 2+, 3+, and 4+, based on the extent of the reaction regardless of previous diagnosis. Results: Positive reaction with cytokeratin-19 was denoted in all of the 45 cases of papillary carcino mas with scores of 4+, 3+ and 2+ and the ratios were 57.8% (26/45), 33.3% (15/45) and 8.9% (4/45), respectively. There seemed to be a strong diffuse cytoplasmic reactivity with cytokeratin-19 in papillary thyroid carcinomas. The sensitivity and specificity for cytokeratin-19 in papillary carcinomas among neoplastic thyroid lesions were 91.8% and 86.2%, respectively. Conclusion: In additi on to careful histological evaluation, cytokeratin-19 seems useful for the diagnosis of papillary thyroid carcinomas. Copyright © 2009 by Türkiye Klinikleri Daha fazlası Daha az

6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms